<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67139">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01912339</url>
  </required_header>
  <id_info>
    <org_study_id>2105-001</org_study_id>
    <nct_id>NCT01912339</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)</brief_title>
  <acronym>REZUM</acronym>
  <official_title>Minimally Invasive Prostatic Vapor Ablation - Multicenter, Controlled Study for the Treatment of BPH (Rezūm II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NxThera Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NxThera Inc</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of the Rezūm System and assess its effect on urinary
      symptoms secondary to benign prostatic hyperplasia (BPH).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, controlled, randomized single blind clinical trial of subjects
      with benign prostatic hyperplasia, which will allow for an interim analysis for sample size
      adjustment.  Subjects first will be randomized in a 2:1 proportion in favor of the Treatment
      arm.  Subjects in the Control arm will be allowed to crossover to have the Rezūm treatment
      after the 3-month follow-up examination.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Efficacy: International Prostate Symptom Score (IPSS)</measure>
    <time_frame>3 Month Follow-up Visit</time_frame>
    <safety_issue>No</safety_issue>
    <description>Comparison of the change in BPH symptoms as measured by IPSS change between the Treatment and Control arm at 3 months post-treatment.  The IPSS is a well-validated, highly reliable and responsive American Urological Association symptom score (AUASS) assessment to identify the severity of BPH Symptoms.  The first seven questions of the IPSS Questionnaire address frequency, nocturia, weak urinary stream, hesitancy, intermittence, incomplete emptying and urgency.   The eighth question is designed to assess the degree of &quot;bother&quot; associated with the subject's urinary symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Device Related Serious Complications</measure>
    <time_frame>3 Months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>This safety endpoint will be to demonstrate that the composite observed rate of post-procedure device related serious complications in the Treatment Arm are is less than or equal to 12% at 3 months.
Composite device related serious complications for this endpoint are 1) De Novo (new) severe urinary retention lasting more than 21 consecutive days post treatment, 2) Device related formation of fistula between the rectum and urethra, and 3) device perforation of the rectum or GI tract.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Responders at 3 Months</measure>
    <time_frame>3 Months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Responders at 6 Months</measure>
    <time_frame>6 Months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Responders at 12 Months</measure>
    <time_frame>12 Months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">195</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <condition>Lower Urinary Tract Symptom</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment: Rezūm System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Control: Rigid Cystoscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Rezum System</intervention_name>
    <description>The Rezūm System uses sterile water vapor (steam) to treat BPH by delivering targeted, controlled doses of stored thermal energy directly to the transition zone of the prostate gland.
A narrow sheath, similar in shape and size to a cystoscope, is inserted transurethrally and positioned within the prostatic urethra between the bladder neck and the verumontanum.
A thin needle is deployed through the urethra into the transition zone, and a very short (8-10 second) treatment of water vapor is delivered directly into the hyperplastic tissue and immediately disperses through the tissue interstices.
Upon contact with the tissue, the vapor condenses, or phase shifts, into its liquid state, releasing the stored thermal energy contained within the vapor.  This thermal energy is released directly against the walls of the tissue cells within the treatment zone, gently and immediately denaturing the cell membranes, thereby causing instantaneous cell death.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Rigid Cystoscopy</intervention_name>
    <description>Endoscopy of the urinary bladder via the urethra.</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Cystoscopy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male subjects &gt; 50 years of age who have symptomatic BPH.

          2. International Prostate Symptom Score (IPSS) score ≥ 13.

          3. Peak urinary flow rate (Qmax): ≥ 5ml/sec to ≤ 15 ml/sec with minimum voided volume of
             ≥ 125 ml.

          4. Post-void residual (PVR) ≤250 ml.

          5. Prostate volume &gt; 30 and ≤ 80 gm.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claus Roehrborn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevin McVary, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southern Illinois University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cindy B Ogden</last_name>
    <phone>763-515-2388</phone>
    <email>cogden@nxthera.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrea R Stone</last_name>
    <phone>763-515-0065</phone>
    <email>astone@nxthera.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arizona Institute of Urology</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Snyder, RN</last_name>
      <phone>520-784-7019</phone>
      <email>ssnyder@aiurology.com</email>
    </contact>
    <investigator>
      <last_name>Jerry M Greenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kalpesh R. Patel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urology Associates of Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keith Gryder-Childers</last_name>
      <phone>303-733-8848</phone>
      <phone_ext>7</phone_ext>
      <email>k.gryder@uradenver.com</email>
    </contact>
    <investigator>
      <last_name>Barrett Cowan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Florida Medical Research</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sayonara Nunez</last_name>
      <phone>305-931-8080</phone>
      <email>snunez@southfloridamedicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Marc Gittelman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern Illinois University</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristal Adams</last_name>
      <phone>217-545-7812</phone>
      <email>kadams@siumed.edu</email>
    </contact>
    <investigator>
      <last_name>Kevin McVary, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology</name>
      <address>
        <city>Townson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crystal Vaughan</last_name>
      <phone>443-471-5725</phone>
      <email>cvaughan@cua.md</email>
    </contact>
    <investigator>
      <last_name>Richard Levin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Smith, R.N.</last_name>
      <phone>507-266-8788</phone>
      <email>smith.jane2@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Lance Mynderse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Metro Urology</name>
      <address>
        <city>Woodbury</city>
        <state>Minnesota</state>
        <zip>55125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Holtz</last_name>
      <phone>651-999-7033</phone>
      <email>choltz@metro-urology.com</email>
    </contact>
    <investigator>
      <last_name>Randy Beahrs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manhattan Medical Research</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmela Graci-Pipitone</last_name>
      <email>cgpipitone@manhattanmedicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Jed Kaminetsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Urology Group</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Corbet</last_name>
      <phone>513-841-7555</phone>
      <email>wcorbett@theurologygroup.net</email>
    </contact>
    <investigator>
      <last_name>Michael Rousseau, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Hayword</last_name>
      <email>haywooc@ccf.org</email>
    </contact>
    <investigator>
      <last_name>James Ulchaker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolina Urologic Research Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Baiden</last_name>
      <phone>843-449-1010</phone>
      <phone_ext>237</phone_ext>
      <email>jbaiden@grandstrandurology.com</email>
    </contact>
    <investigator>
      <last_name>Neal Shore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Urology</name>
      <address>
        <city>Carrolton</city>
        <state>Texas</state>
        <zip>75010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simona Marin</last_name>
      <email>smarin@researchacrossamerica.com</email>
    </contact>
    <investigator>
      <last_name>Kenneth Goldberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Beaver</last_name>
      <phone>214-645-8787</phone>
      <email>allison.beaver@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Claus Roehrborn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urology of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Perez</last_name>
      <phone>210-617-4116</phone>
      <email>jlp@urologysaresearch.com</email>
    </contact>
    <investigator>
      <last_name>Christopher Cantrill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jean Brown Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Griffiths</last_name>
      <email>sgriffiths@jbrutah.com</email>
    </contact>
    <contact_backup>
      <phone>(801) 261-2000</phone>
      <phone_ext>324</phone_ext>
    </contact_backup>
    <investigator>
      <last_name>Steven Gange, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 31, 2014</lastchanged_date>
  <firstreceived_date>July 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperlasia</keyword>
  <keyword>Retention</keyword>
  <keyword>Prostate</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
